Australian medical technology firm LBT Innovations Limited (ASX: LBT) announces the successful primary validation of APAS® PharmaQC, marking the culmination of its development and commercialization efforts. The validation, conducted to pharmacopeial requirements, confirms APAS® PharmaQC as a reliable alternative in microbiology automation. With over 35,000 plate images analyzed and meeting all performance targets, the technology enhances quality control and data integrity in pharmaceutical manufacturing.
This validation paves the way for broader commercial opportunities, eliminating the need for additional regulatory approvals. AstraZeneca Plc will conduct internal validation, expecting completion by Q3 2024. CEO Brent Barnes highlights the significance of evidence-based automation in biopharmaceuticals, anticipating accelerated adoption fueled by positive customer feedback and ambitious commercialization plans. The study underscores APAS® PharmaQC's efficacy with zero false-negative rates and precise colony counting, consolidating its credibility in the market.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
